TELA TELA Bio Inc

TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, announced today that it took part in a segment in Connecting the Dots, a series of branded films presented by MedTech Europe and including a film produced for them by BBC StoryWorks Commercial Productions.

The Connecting the Dots series will include a mini-documentary style film, A Perfect Match, produced for TELA Bio highlighting the use of OviTex® Reinforced Tissue Matrix in hernia repair. Annually, surgeons perform an estimated 20 million hernia repair procedures worldwide. Most of these surgeries involve the use of a mesh implant to strengthen the repair and minimize the risk of recurrence. While a range of hernia reinforcement options exists, including permanent plastic and tissue-derived materials, many prospective patients may not be aware of the newer alternatives available for their hernia surgery.

Connecting The Dots is a new series of branded films presented by MedTech Europe. The series aims to showcase the role of medical technologies in improving the healthcare landscape across the globe and is available at https://www.bbc.com/storyworks/specials/connecting-the-dots/.

“We’re thrilled to take part in this series,” said Antony Koblish, President and CEO of TELA Bio. "This project presents a unique opportunity to educate the public about OviTex and its role in evolving hernia treatment for surgeons and patients.”

For more information about OviTex Reinforced Tissue Matrix, visit telabio.com.

About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

About OviTexOviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Do not use OviTex in patients known to be sensitive to materials of ovine (sheep) origin. For prescription use only. For additional important safety information, please see the OviTex Reinforced Tissue Matrix Instructions for Use.

Caution Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor ContactGreg Chodaczek347-620-7010ir@telabio.com    

Media ContactAndie Levine610-724-5044andie@0to5.com